Resources and events
Browse our collection of resources and explore upcoming stands and symposiums where the JARDIANCE® team will be present. We look forward to meeting you.
JARDIANCE® patient booklets
JARDIANCE® CRM patient booklet
Podcast series
Checklist for pharmacists when diagnosing and treating CKD
Advertorial on the role of pharmacists in diagnosing and treating CKD
Sick Day Rules
JARDIANCE® Initiation & Management guide for T2D, CHF and CKD
Identify patients who could benefit from JARDIANCE®
Watch Dr Jarvis and Dr Javaid discuss which patients may be suitable for empagliflozin treatment
21st National Primary Care Diabetes & Obesity (PCDO) Society Conference
PC-GB-110623 V5 | November 2025
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.
- JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-109995 V4 | October 2025